Finally, a win for Illumina — for whom it’s been doom and gloom for quite some time, after an $8 billion effort to acquire Grail was blocked by European regulators. Now, Nicholas Emiliou, advocate general of the Court of Justice of the EU, has said that decision was wrong and ought to be reversed, Financial Times writes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,